PEN
Penumbra, Inc.NYSEHealthcare$330.36+0.43%OpenMarket Cap: $12.96B
As of 2026-04-06
Valuation
P/E (TTM)
72.96
PEG
0.06
P/B
9.07
P/S
9.24
EV/EBITDA
58.13
DCF Value
$-94.87
FCF Yield
1.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.1%
Operating Margin
13.5%
Net Margin
12.7%
ROE
13.4%
ROA
10.7%
ROIC
9.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $385.4M | 68.0% | $59.2M | $47.3M | $1.20 | — |
| FY 2025 | $1.40B | 67.1% | $189.2M | $177.7M | $4.52 | — |
| Q3 2025 | $354.7M | 67.8% | $48.8M | $45.9M | $1.17 | — |
| Q2 2025 | $339.5M | 66.0% | $40.8M | $45.3M | $1.15 | — |
| Q1 2025 | $324.1M | 66.6% | $40.4M | $39.2M | $1.00 | — |
| Q4 2024 | $315.5M | 66.8% | $42.8M | $33.7M | $0.86 | — |
| FY 2024 | $1.19B | 63.2% | $9.3M | $14.0M | $0.36 | — |
| Q3 2024 | $301.0M | 66.5% | $35.4M | $29.5M | $0.75 | — |
| Q2 2024 | $299.4M | 54.4% | $-81.0M | $-60.2M | $-1.55 | — |
| Q1 2024 | $278.7M | 65.0% | $12.1M | $11.0M | $0.28 | — |
| Q4 2023 | $284.7M | 65.7% | $35.0M | $54.2M | $1.38 | — |
| FY 2023 | $1.06B | 64.5% | $73.6M | $91.0M | $2.32 | — |